{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Gastric+Cancer&page=2", "query": { "condition": "Locally Advanced Gastric Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Gastric+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T16:41:47.883Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04672434", "title": "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym024", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-11-19", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04672434" }, { "nct_id": "NCT00004233", "title": "S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "triacetyluridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2001-02", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 97, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004233" }, { "nct_id": "NCT03281369", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma" ], "interventions": [ { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "PEGylated recombinant human hyaluronidase (PEGPH20)", "type": "BIOLOGICAL" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Linagliptin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2017-10-13", "completion_date": "2025-10-09", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03281369" }, { "nct_id": "NCT01896531", "title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2013-08-14", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896531" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 296, "start_date": "2019-12-10", "completion_date": "2027-05-12", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-Oesophageal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine/Tipracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Australasian Gastro-Intestinal Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2021-05-05", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879368" }, { "nct_id": "NCT07454642", "title": "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Vulvar Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Small Cell Carcinoma of Lung", "Colorectal Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "AVA6103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avacta Life Sciences Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2026-03-31", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Irving", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07454642" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" }, { "nct_id": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Colorectal Cancer", "HER2-expressing Non-small Cell Lung Cancer" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "trastuzumab deruxtecan", "type": "DRUG" }, { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-02-08", "completion_date": "2022-07-07", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091528" }, { "nct_id": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "ramucirumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tucatinib placebo", "type": "OTHER" }, { "name": "trastuzumab placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-06-25T16:41:47.883Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04499924" } ] }